Novavax's (NVAX.US) share price jumped more than 20% after the biotech company said Canada had agreed to pay $350 million for Covid vaccines that were previously due to be delivered. The settlement, in the case of NVAX, is significant because the company's management expressed doubts about its viability earlier in the year.
According to the SEC filing, the Canadian government's payment will be made in two equal instalments in 2023. It is worth mentioning that the vaccines for Covid-19 are the company's only commercial product.
The company's shares are currently testing the limitation formed by the 100-day exponential moving average (purple curve). Source: xStation 5
Dailu summary: Sell-off on Wall street 📉 Bitcoin and Ethereum extend downfall in panic
Software stocks in panic mode 📉Will Anthropic AI disrupt tech valuations?
US100 loses 2% 📉
The launch of Xeon 600 and cooperation with SoftBank. Is this a breakthrough for Intel?